化疗引起的周边神经病变（CIPN）：市场展望、流行病学、竞争格局、市场预测报告（2025-2035）

市场概览

• 德国市场预计将从约 1.7 亿美元成长到约 2.9 亿美元（年复合成长率约 5-6%）。
• 推动这一成长的动力是对支持性护理的需求和未被满足的需求，目前还没有核准的预防性疗法。

化疗引起的周边神经病变（CIPN）概述

化疗引起的周边神经病变（CIPN）是一种常见的、通常是剂量限制性的毒性反应，与神经毒性抗癌药物有关，特别是紫杉烷类、含铂类药物和长春花生物碱类药物。它是由周围神经系统的多因素损伤引起的，包括轴突变性、粒线体功能障碍以及背根神经节的直接损伤，背根神经节由于其高代谢活性和血神经屏障渗透性而高度易感。

临床上，化疗诱发週边神经病变（CIPN）表现为对称性感觉神经病变，呈现「手套袜套样」分布，其特征为麻木、刺痛（感觉异常）和灼痛。一个显着的特征是「症状持续加重」现象，即使停止化疗后症状仍会继续恶化。

危险因子包括药物累积暴露、高龄、糖尿病等合併症。目前尚无核准的预防性治疗方法，治疗仅限于症状治疗。Duloxetine（SNRI）是唯一有实证医学证据支持的药物治疗选择，但严重的神经病变通常需要减重或停止化疗，影响癌症治疗效果。

主要亮点

• CIPN 是一种常见的剂量限制性毒性，会影响癌症治疗和患者的生活品质。
• 美国（替代人口）的癌症病例数预计将从约 174 万例增加到约 183 万例（年均复合成长率约 0.5%）。

格式化和更新讯息

• 详细报告（PDF）
• 市场预测模型（基于微软Excel）
• 流行病学数据（MS Excel，互动式工具）
• 高阶主管洞察（PPT简报）
• 其他功能：定期更新、自订和顾问支援。
• 根据 Thelansis 的政策，我们确保所有最新更新在发布前都反映在报告内容和市场模型中。

主要问题

• 我们如何优化 G8 市场（美国、欧盟 5 国、日本、中国）的药物开发与生命週期管理策略？
• 从发病率、盛行率、人群组成以及接受药物治疗的患者人数来看，患者数量分别是多少？
• 未来十年市场收入和病患份额的预测是多少？
• 哪些因素对市场趋势影响最大？
• 受访专家对目前和新兴的治疗方法有何看法？
• 哪款在研发线产品最有前景？其上市潜力及未来市场定位如何？
• 主要未被满足的需求是什么？ KOL 对目标受众有何期望？
• 为确保药物核准并顺利进入市场，必须满足哪些关键的监管和支付方要求？

目标国家

• G8
  • 我们
  • EU5
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 英国
  • 日本
  • 中国

大公司

• Tarian Pharma
• Ono Pharmaceutical Co. Ltd
• Akeso
• Qilu Pharmaceutical Co., Ltd.
• VM Therapeutics LLC
• Dogwood Therapeutics Inc.

目录

第一章：主要调查结果及分析师说明

• 主要趋势：市场概况、SWOT分析、商业性利益与风险等。

第二章：疾病背景

• 疾病定义、分类、病因和病理生理学、药物标靶等。

第三章：流行病学

• 重点
• 发病率/盛行率
• 已确诊并接受药物治疗的患者人数
• 合併症
• 其他相关患者群

第四章 市场规模及预测

• 重点
• 市场驱动因素与限制因素
• 按药物类别分類的趋势
• 各国具体趋势

第五章 竞争情势

• 目前的治疗方法
  • 重点
  • 诊断和治疗过程/演算法
  • 主要治疗方法概述及KOL洞察
• 新兴治疗方法
  • 重点
  • 值得关注的后期新治疗方法－概述、市场上市预期及KOL洞察
  • 值得关注的早期研发管线

第六章：未满足的需求与TPP分析

• 主要未满足的需求以及透过新兴治疗方法实现的未来可能性
• TPP分析与KOL展望

第七章 监理与报销环境

第八章附录

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market Outlook

Thelansis's "Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chemotherapy-Induced Peripheral Neuropathy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Overview

Chemotherapy-induced peripheral neuropathy (CIPN) is a prevalent and often dose-limiting toxicity associated with neurotoxic anticancer agents, particularly taxanes, platinum compounds, and vinca alkaloids. It arises from multifactorial damage to the peripheral nervous system, including axonal degeneration, mitochondrial dysfunction, and direct injury to dorsal root ganglia, which are highly susceptible due to their metabolic activity and permeable blood-nerve barrier.

Clinically, CIPN presents as a symmetric sensory neuropathy in a "glove-and-stocking" distribution, characterized by numbness, tingling (paresthesia), and burning pain. A notable feature is the "coasting" phenomenon, where symptoms continue to worsen even after cessation of chemotherapy.

Risk factors include cumulative drug exposure, advanced age, and comorbidities such as diabetes. Currently, there are no approved therapies for prevention, and management remains symptomatic. Duloxetine (SNRI) is the only evidence-based pharmacologic option, while severe neuropathy often necessitates dose reduction or discontinuation of chemotherapy, impacting cancer treatment outcomes.

Key Highlights

• CIPN is a common, dose-limiting toxicity impacting cancer treatment and patient quality of life
• US cancer incidence (proxy population) expected to grow from ~1.74M to ~1.83M (~0.5% CAGR)

Market Overview

• Germany market projected to grow from ~$170M to ~$290M (~5-6% CAGR)
• Growth driven by supportive care demand and unmet need, with no approved preventive therapies

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• Tarian Pharma
• Ono Pharmaceutical Co. Ltd
• Akeso
• Qilu Pharmaceutical Co., Ltd.
• VM Therapeutics LLC
• Dogwood Therapeutics Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)